Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft.

BMC cancer - 31 Dec 2025

Han Pinsheng, Zhu Liuyang, Tong Wen, Liu Sen, Xu Yongdeng, Wang Libo, Wang Tianze, Zhao Tianyu, Miao Yu, Chi Hao, Cui Tao, Wang Ze, Yang Long, Zhang Yamin

Abstract excerpt

INTRODUCTION: Cholangiocarcinoma (CCA) is a highly aggressive biliary malignancy with a very poor prognosis. How to screen the optimal chemotherapy regimen is crucial for enhancing the prognosis of CCA patients. The study aims to develop patient-derived tumor organoid (PDO) models and patient-derived tumor xenograft (PDX) models of CCA to simulate clinical responses to chemotherapy. METHODS: Tumor tissues were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Drug Screening Assays, Antitumor

Share to Exome Sequencing

Share to Organoids

Share to Precision Medicine

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41469951
DOI: 10.1186/s12885-025-15495-w
PMCID: PMC12870517

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft.PMID 41469951Read ↗

Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical applicationSemantic proximity Read ↗

Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoidsSemantic proximity Read ↗

Establishment of Highly Transplantable Cholangiocarcinoma Cell Lines from a Patient-Derived Xenograft Mouse ModelSemantic proximity Read ↗

Application and mechanism of anticancer peptides in organoid models of intrahepatic cholangiocarcinomaSemantic proximity Read ↗

Establishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinomaSemantic proximity Read ↗

Establishment and Drug Screening of Patient-Derived Extrahepatic Biliary Tract Carcinoma OrganoidsSemantic proximity Read ↗

Precision Medicine in Cholangiocarcinoma: Past, Present, and FutureSemantic proximity Read ↗

Update on cholangiocarcinoma: potential impact of genomic studies on clinical management.Semantic proximity Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

Cholangiocarcinoma Disease Modelling Through Patients Derived OrganoidsSemantic proximity Read ↗

Molecular Subtypes and Precision Oncology in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.